Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists.
Glatzer M, Leskow P, Caparrotti F, Elicin O, Furrer M, Gambazzi F, Dutly A, Gelpke H, Guckenberger M, Heuberger J, Inderbitzi R, Cafarotti S, Karenovics W, Kestenholz P, Kocher GJ, Kraxner P, Krueger T, Martucci F, Oehler C, Ozsahin M, Papachristofilou A, Wagnetz D, Zaugg K, Zwahlen D, Opitz I, Putora PM. Glatzer M, et al. Among authors: ozsahin m. Transl Lung Cancer Res. 2021 Apr;10(4):1960-1968. doi: 10.21037/tlcr-20-1210. Transl Lung Cancer Res. 2021. PMID: 34012806 Free PMC article.
Primary breast lymphoma: patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study.
Jeanneret-Sozzi W, Taghian A, Epelbaum R, Poortmans P, Zwahlen D, Amsler B, Villette S, Belkacémi Y, Nguyen T, Scalliet P, Maingon P, Gutiérrez C, Gastelblum P, Krengli M, Raad RA, Ozsahin M, Mirimanoff RO. Jeanneret-Sozzi W, et al. Among authors: ozsahin m. BMC Cancer. 2008 Apr 1;8:86. doi: 10.1186/1471-2407-8-86. BMC Cancer. 2008. PMID: 18380889 Free PMC article.
[(18)F]FDG-PET standard uptake value as a metabolic predictor of bone marrow response to radiation: impact on acute and late hematological toxicity in cervical cancer patients treated with chemoradiation therapy.
Elicin O, Callaway S, Prior JO, Bourhis J, Ozsahin M, Herrera FG. Elicin O, et al. Among authors: ozsahin m. Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1099-107. doi: 10.1016/j.ijrobp.2014.08.017. Epub 2014 Oct 13. Int J Radiat Oncol Biol Phys. 2014. PMID: 25442041
Current Role of Dacomitinib in Head and Neck Cancer.
Elicin O, Ozsahin M. Elicin O, et al. Among authors: ozsahin m. Expert Opin Investig Drugs. 2016 Jun;25(6):735-42. doi: 10.1080/13543784.2016.1177022. Epub 2016 May 3. Expert Opin Investig Drugs. 2016. PMID: 27070370 Review.
Influencing Factors on Radiotherapy Outcome in Stage I-II Glottic Larynx Cancer-A Multicenter Study.
Elicin O, Ermiş E, Oehler C, Aebersold DM, Caparrotti F, Zimmermann F, Studer G, Henke G, Adam L, Anschuetz L, Ozsahin M, Guckenberger M, Shelan M, Kaydıhan N, Riesterer O, Prestwich RJD, Spielmann T, Giger R, Şen M. Elicin O, et al. Among authors: ozsahin m. Front Oncol. 2019 Sep 20;9:932. doi: 10.3389/fonc.2019.00932. eCollection 2019. Front Oncol. 2019. PMID: 31616637 Free PMC article.
Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO).
Allal AS, Ares C, Dulguerov P, Tschanz E, Verdan C, Mhawech P, Riesterer O, Honer M, Vuong V, Jochum W, Zingg D, Bodis S, Ametamey S, Pruschy M, Inteeworn N, Ohlerth S, Höpfl G, Roos M, Wergin M, Rohrer Bley C, Gassmann M, Kaser-Hotz B, Berthou S, Aebersold DM, Ganapathipillai S, Streit B, Stalder D, Gruber G, Greiner RH, Zimmer Y, Lutters G, Krek W, Tenzer A, Hofstetter B, Bonny C, Azria A, Larbouret C, Cunat S, Ozsahin M, Zouhair A, Gourgou S, Martineau P, Evans DB, Romieu G, Pujol P, Pèlegrin A, Heuberger J, Kestenholz P, Taverna Ch, Lardinois D, Jörger M, Schneiter D, Jerman M, Weder W, Stahel R, Bodis S, Vees H, Mach N, Hügli A, Balmer Majno S, Beer KT, Friedrich EE, Ciernik IF, Stanek N, Taverna C, Greiner R, Mahler F, Landmann Ch, Studer G, Bernier J, Gallino A, Juelke PD, Hafner HP, Jamshidi P, Erne P, Resink TJ, Thum P, Notter M, Bargetzi M, Suleiman M, Luthi JC, Bieri S, Curschmann J, Pajic B, Kranzbühler H, Lippold B, Ueltschi G, Bonetti M, Nasi ML, Price KN, Castiglione-Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J, Gol-Ouh R, Collins J, Crivellari D, Carbone A, Thürlimann B, Simoncini E, Fey MF, Gelber RD, Coates AS, Goldhirsch A, Jeanneret Sozzi W, Kramar A… See abstract for full author list ➔ Allal AS, et al. Among authors: ozsahin m. Strahlenther Onkol. 2004 Jun;180 Suppl 1:89-108. doi: 10.1007/BF03356735. Strahlenther Onkol. 2004. PMID: 27137923 No abstract available.
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
Peters S, Dafni U, Boyer M, De Ruysscher D, Faivre-Finn C, Felip E, Garrido P, Girard N, Guckenberger M, Haanen J, Le Pechoux C, Mornex F, Ozsahin M, Paz-Ares L, Planchard D, Raben D, Ramalingam S, Reck M, Smit E, Stahel R, Stenzinger A, Swanton C, Vallone S, Garassino MC. Peters S, et al. Among authors: ozsahin m. Ann Oncol. 2019 Feb 1;30(2):161-165. doi: 10.1093/annonc/mdy553. Ann Oncol. 2019. PMID: 30624547 Free article. No abstract available.
280 results